8th ESO-CNIO Conference on Familial Cancer

Chairs: R. Eeles, UK - W. Foulkes, CA - M. Robledo, ES - H. Vasen, NL


The ESO and CNIO Conference on Familial Cancer aims to present the advances in this field from a multidisciplinary point of view. Due to its implications not only at individual but also at the familial and social level, familial cancer has become an important challenge for oncologists, geneticists, molecular biologists and other professionals.. Along the last years, new approaches have allowed to increase our knowledge about the genes responsible for familial cancer as well as their biological functions – factors that are essential in identifying the appropriate treatment in each case. The next generation sequencing is extensively used in the search of causal mutations but it represents a new challenge regarding the interpretation of variants, many of which must be classified as of unknown significance. Biannually the Conference brings together leading basic and translational researchers and clinicians involved in the diagnosis, treatment and follow-up of patients with familial cancer. These meetings help to establish connections among professionals that in turn promote progress in the understanding and treatment of these diseases. Besides the lectures from international experts, young scientists can present their work as short lectures and posters. This format aims to facilitate extensive discussion of current issues and stimulate new ideas.

LEARNING OBJECTIVES
• Improve the understanding of the selection criteria the landscape of breast and ovarian cancer genes, and their clinical impact
• Update the knowledge about genetics and clinical management of hereditary colorectal cancer
• Appraise herapeutic strategies in the era of personalized medicine and implications of applying next generation sequencing to the diagnosis
• Learn about translating genetic risk factors to the surveillance and clinical management of prostate cancer
• Update the knowledge about rare cancers: new genes, new approaches, new challenges.

MAIN TOPICS
• Breast and ovarian cancer
• Colon and prostate cancer
• Rare cancers
• Implications of applying next generation sequencing to the diagnosis

In cooperation with:

FACULTY
A. Antoniou, University of Cambridge, UK
S. Aretz, Institute of Human Genetics, University of Bonn, DE
J. Benitez, Centro Nacional de Investigaciones Oncólogicas (CNIO), Madrid, ES
I. Blanco, Hospital Germans Trias i Pujol, Barcelona, ES
P. Devilee, Leiden University Medical Centre, NL
R. Eeles, NHS Trust and the Institute for Cancer Research, Sutton, UK
W.D. Foulkes, Lady Davis Institute for Medical Research, Montreal, CA
H. Hanson, St George’s Hospital, London, UK
T. Links, University of Groningen, NL
J.A. Newton-Bishop, University of Leeds, UK
A. Osorio, Centro Nacional de Investigaciones Oncólogicas (CNIO), Madrid, ES
B. Paumard, Institute of Medical and Molecular Genetics (INGEMM), Hospital La Paz Institute for Research Help (Idipaz), Madrid, ES
G. Pichert, OnkoZentrum Hirslanden, Zurich, CH
M. Robledo, Centro Nacional de Investigaciones Oncólogicas (CNIO), Madrid, ES
M. Soengas, Centro Nacional de Investigaciones Oncólogicas (CNIO), Madrid, ES
D. Stoppa-Lyonnet, Institut Curie, Paris, FR
S. Syngal, Dana Farber Cancer Institute, Boston, US
H. Vasen, Leiden University Medical Centre, NL
K. Wimmer, Medical University Innsbruck, AT

ORGANISING SECRETARIAT
Daniela Mengato
European School of Oncology (ESO)
Via Turati 29 - 20121 Milan, Italy
Tel: +39 02 854 64523
Fax: +39 02 85464545
Email: dmengato@eso.net

Registrations:
Luis Carvalho, lcarvalho@eso.net, ph +41 91 820 0958

VENUE
Centro Nacional de Investigaciones Oncólogicas (CNIO)
Calle Melchor Fernández Almagro, 3
Madrid, Spain
www.cnio.es

OFFICIAL LANGUAGE
The official language will be English. No translation will be provided.

BADGE
The badge is the only official evidence of registration and should be worn at all times during the event. Loss of badge causes loss of registration.

INSURANCE
The organisers bears no responsibility for untoward in relation to the participation in the Conference. Participants are advised to take out their own personal and travel insurance coverage.

CME ACCREDIATION CERTIFICATES
Participants will be issued a certificate of attendance. The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value. The event is designated for a maximum of 10 European CME credits (ECMEC). Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

 17 May

18 May